BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)
Published: Sept. 30, 2024
Language: Английский
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Aug. 5, 2024
Hepatocellular carcinoma (HCC) is one of the most common cancers and third leading cause death worldwide. surgery, transarterial chemoembolization (TACE), systemic therapy, local ablation radiotherapy, targeted drug therapy with agents such as sorafenib. However, tumor microenvironment liver cancer has a strong immunosuppressive effect. Therefore, new treatments for are still necessary. Immune checkpoint molecules, programmed death-1 (PD-1), death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), along high levels cytokines, induce cell inhibition key mechanisms immune escape in HCC. Recently, immunotherapy based on inhibitors (ICIs) monotherapy or combination tyrosine kinase inhibitors, anti-angiogenesis drugs, chemotherapy agents, topical therapies offered great promise treatment cancer. In this review, we discuss latest advances ICIs combined drugs (targeted-immune combination) other targeted-immune regimens patients advanced HCC (aHCC) unresectable (uHCC), provide an outlook future prospects. The literature reviewed spans last five years includes studies identified using keywords "hepatocellular carcinoma," "immune inhibitors," "targeted therapy," "combination "immunotherapy".
Language: Английский
Citations
9
Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 12
Published: April 16, 2025
Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths globally. Despite advances in targeted therapy and immunotherapy, survival rates for advanced HCC remain low. Combining hepatic artery infusion chemotherapy (HAIC) with systemic therapies shows potential, but identifying patients who benefit most challenging. Body composition, including sarcopenia myosteatosis, has been linked to cancer prognosis, its role receiving HAIC immunotherapies unclear. This retrospective study analyzed 158 treated HAIC, tyrosine kinase inhibitors, anti-PD-1 immunotherapy from January 2021 October 2024. composition was assessed via CT scans at the L3 level, defined by skeletal muscle index (SMI) myosteatosis density (SMD). Progression-free (PFS) overall (OS) were evaluated, Cox regression analyses identified prognostic factors. Sarcopenia cutoffs 47.1 cm2/m2 (males) 38.2 (females); 40.8 HU 38.9 (females). Sarcopenic had lower BMI (p < 0.001) higher ALBI scores = 0.006). Tumor response (ORR 53.4%, DCR 77.9%) similar between sarcopenic non-sarcopenic groups 0.531 p 0.699). Myosteatosis showed no significant differences ORR (54.0%) or (77.0%) 0.693 0.872). Median PFS did not differ (9.53 months) (13.87 0.536). However, significantly shorter OS (20.80 vs. 35.97 months, 0.005). also correlated 0.021). Multivariate analysis as an independent risk factor (HR: 0.527, 0.017), alongside AFP levels tumor number. predict poor prognosis immunotherapy. OS, highlighting importance body prognosis. No associations found PFS.
Language: Английский
Citations
0
Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)
Published: Aug. 27, 2024
This study aims to examine the possible relationship between body composition parameters, sarcopenia, and clinical outcomes in hepatocellular carcinoma (HCC) patients who received immune checkpoint inhibitor (ICI) treatment.
Language: Английский
Citations
2
BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)
Published: Sept. 30, 2024
Language: Английский
Citations
0